Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

Sep 1, 2026, 10:15 AM

Read Full Article → Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

Translate article text

Choose a language and wait for the translated text.

Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal | PharmaVoice